Drug manufacturer JCR announced last month that it has submitted a marketing approval in Japan for JR-051, a proposed agalsidase beta biosimilar referenced on Fabrazyme.
Drug manufacturer JCR announced last month that it has submitted a marketing approval in Japan for JR-051, a proposed agalsidase beta biosimilar referenced on Fabrazyme. JCR developed the drug in partnership with Amicus Therapeutics and GlaxoSmithKline.
JR-051, like its reference, is a recombinant human alpha-galactosidase A enzyme replacement therapy that is used to treat Fabry’s disease (FD), a rare, inherited disorder that affects 1 in 40,000 to 60,000 men (the disorder can also occur in women, though its prevalence is not known). The result of a mutation in the alpha-galactosidase A gene, patients with FD have a buildup of globotriaosylceramide in cells, which can adversely affect the functioning of the heart, kidneys, and other organs and lead to cardiac disease, stroke, renal failure, and early death.
According to a paper in Genetics in Medicine, the reference agalsidase beta, manufactured by Sanofi Genzyme, was subject to a global shortage in 2009 after a manufacturing process introduced viral contamination into the drug supply. During the shortage, patients were instructed by the European Medicines Agency (EMA) to reduce their dosages. An increased rate of serious adverse events associated with the drug was observed among patients who followed directions to reduce their doses, and the EMA subsequently recommended switching patients to other therapies.
The shortage posed such a dire risk for US patients with FD that patients petitioned the federal government to allow a Bayh-Dole “march-in” proceeding that would force Sanofi Genzyme to license its patent for the drug to additional drug makers. The National Institutes of Health determined that a march-in proceeding was not warranted, largely because a granting patent use rights to a third party would not solve the problem of the drug shortage in the short term, as clinical studies and regulatory approval would still be required before a biosimilar could be made available to patients in the United States.
Emergence of agalsidase beta biosimilars has the potential to prevent or mitigate the effects of any future shortages for this under-served patient population. Just as importantly, biosimilars have the potential to reduce the extraordinarily high cost of treatment associated with FD. In a report on specialty drugs spending, America’s Health Insurance Plans (AHIP) estimated that the originator agalsidase beta has an average wholesale price of over $300,000 per patient per year. A UK study on the cost effectiveness of enzyme-replacement therapies, including originator agalsidase beta, found that the cost to treat a patient with FD “exceeds the normal upper threshold for cost-effectiveness seen in NHS policy decisions by over six-fold,” but that the health system was left with “no option” but to provide the high-cost therapy.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.